Results 31 to 40 of about 3,197,237 (262)

Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure [PDF]

open access: yes, 2019
Heart failure is a leading cause of mortality, yet our understanding of the genetic interactions underlying this disease remains incomplete. Here, we harvest 1352 healthy and failing human hearts directly from transplant center operating rooms, and ...
Ashley, Euan A.   +34 more
core   +2 more sources

P‐glycoprotein modulates the fluidity gradient of the plasma membrane of multidrug resistant CHO cells

open access: yesFEBS Letters, EarlyView.
To explore the impact of the overexpression of the multidrug‐transporter P‐glycoprotein (ABCB1) on membrane fluidity, we compared the transversal gradient of mobility and microviscosity in plasma membranes of drug‐sensitive Chinese hamster ovary cells (AuxB1) and their multidrug‐resistant derivatives (B30) using the fluorescent n‐(9‐anthroyloxy) fatty ...
Roger Busche   +2 more
wiley   +1 more source

Heart to Heart, May 2013 [PDF]

open access: yes, 2013
Heart to Heart is a publication on new heart disease and stroke information and other related topics by the Department of Public ...

core  

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study [PDF]

open access: yes, 2017
Background: Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in patients with established coronary ...
Allayee, Hooman   +103 more
core   +1 more source

Scleroderma Heart Disease

open access: yesInternational Journal of Immunopathology and Pharmacology, 2005
Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be ...
B. Marasini, M. Massarotti, R. Cossutta
openaire   +4 more sources

Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product

open access: yesMolecular Oncology, EarlyView.
The number of circulating tumor cells obtained from prostate cancer patients was increased approximately 5‐fold compared to regular CellSearch when processing 2 mL diagnostic leukapheresis material aliquots and increased by 44‐fold when processing 20 mL DLA aliquots using the flow enrichment target capture Halbach‐array.
Michiel Stevens   +8 more
wiley   +1 more source

Heart to Heart, February 2013 [PDF]

open access: yes, 2013
Heart to Heart is a publication on new heart disease and stroke information and other related topics by the Department of Public ...

core  

Carcinoid Heart Disease

open access: yesJournal of the American College of Cardiology, 2010
![Figure][1] [![Graphic][3] ][3][![Graphic][4] ][4][![Graphic][5] ][5] A 26-year-old man with a history of carcinoid and small-bowel resection presented with shortness of breath.
Susie N. Hong   +2 more
openaire   +3 more sources

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

open access: yesMolecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy   +12 more
wiley   +1 more source

Heart to Heart, June 2013 [PDF]

open access: yes, 2013
Heart to Heart is a publication on new heart disease and stroke information and other related topics by the Department of Public ...

core  

Home - About - Disclaimer - Privacy